Morphic Holding Inc (MORF)
$28.04
Live
Insights on Morphic Holding Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 60.23M → -60.23M (in $), with an average decrease of 200.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -36.21M → -40.73M (in $), with an average decrease of 12.5% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 84.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 295.3%
Performance
- $27.62$28.78$28.04
1.5%
Downside
Day's Volatility :4.03%
Upside
2.57%
- $19.35$63.08$28.04
30.99%
Downside
52 Weeks Volatility :69.32%
Upside
55.55%
Returns
| Period | Morphic Holding Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 1.73% | 1.9% | 0.0% |
6 Months | 40.31% | 10.7% | 0.0% |
1 Year | -33.95% | 4.6% | -1.1% |
3 Years | -49.12% | 14.2% | -22.1% |
Highlights
Market Capitalization | 1.4B |
Book Value | $14.01 |
Earnings Per Share (EPS) | -3.59 |
Wall Street Target Price | 56.75 |
Profit Margin | 0.0% |
Operating Margin TTM | -34296.74% |
Return On Assets TTM | -20.47% |
Return On Equity TTM | -29.08% |
Revenue TTM | 521.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -31.3M |
EBITDA | -177.6M |
Diluted Eps TTM | -3.59 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.89 |
EPS Estimate Next Year | -4.23 |
EPS Estimate Current Quarter | -0.85 |
EPS Estimate Next Quarter | -0.91 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 102.39%
Technicals Summary
Sell
Neutral
Buy
Morphic Holding Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Morphic Holding Inc | -10.58% | 40.31% | -33.95% | -49.12% | 59.72% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Morphic Holding Inc | NA | NA | NA | -3.89 | -0.29 | -0.2 | NA | 14.01 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Morphic Holding Inc | Buy | $1.4B | 59.72% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Institutional Holdings
FMR Inc
13.56%Wellington Management Company LLP
6.75%BlackRock Inc
6.60%State Street Corporation
5.12%Point72 Asset Management, L.P.
5.01%Vanguard Group Inc
4.64%
Corporate Announcements
Morphic Holding Inc Earnings
Morphic Holding Inc’s price-to-earnings ratio stands at None
Read More
Company Information
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Organization | Morphic Holding Inc |
Employees | 121 |
CEO | Dr. Bruce N. Rogers Ph.D. |
Industry | Health Technology |
